ABSTRACT
This chapter describes a novel nanomedicine that not only increased the immunogenicity of tumor cells and the number of tumor-infiltrating immune cells but also alleviated immunosuppression and improved anti-tumor activity when used in combination with an anti-programmed cell death 1 antibody. Cancer gene therapy and cancer immunotherapy are also considered to be targeted therapies. In gene therapy, the aim is often to restore a particular gene function that is lost or defective in cancer cells or to induce cancer cell death by introducing foreign genetic materials into patient’s cells. The chapter discusses results combining cancer gene therapy and cancer immunotherapy. It also describes SGT-53, a novel nanomedicine that is in human clinical trials for multiple cancer indications. Tumors engage in immunosuppression as part of evading the body’s immune system. The chapter examines the impact of SGT-53 treatment on a number of immune-relevant markers in animals bearing syngeneic tumors.
